• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗冠状动脉支架内再狭窄的生物可吸收血管支架：新曙光还是雪上加霜？

Bioresorbable vascular scaffold for the treatment of coronary in-stent restenosis: New dawn or frost on snow?

作者信息

Ge Junbo

机构信息

Department of Cardiology, Zhongshan Hospital Fudan University, Xuhui District, Shanghai City, China.

出版信息

Catheter Cardiovasc Interv. 2018 Oct 1;92(4):678-679. doi: 10.1002/ccd.27880.

DOI:10.1002/ccd.27880
PMID:30341828
Abstract

BVS might be non-inferiority compared to DES or DEB in ISR treatment in terms of 1-year DOCE. BVS, especially thinner-strut stent may be an attractive alternative in ISR setting. Large prospective randomized trials are needed to provide convince evidences to direct clinical practice in the future.

摘要

就1年的药物洗脱完全闭塞而言，在支架内再狭窄（ISR）治疗中，生物可吸收支架（BVS）可能不劣于药物洗脱支架（DES）或药物洗脱球囊（DEB）。BVS，尤其是支架小梁更薄的支架，在ISR治疗中可能是一种有吸引力的替代选择。需要开展大型前瞻性随机试验，以提供确凿证据，指导未来的临床实践。

相似文献

1
Bioresorbable vascular scaffold for the treatment of coronary in-stent restenosis: New dawn or frost on snow?用于治疗冠状动脉支架内再狭窄的生物可吸收血管支架：新曙光还是雪上加霜？
Catheter Cardiovasc Interv. 2018 Oct 1;92(4):678-679. doi: 10.1002/ccd.27880.
2
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).生物可吸收血管支架与依维莫司洗脱支架或药物洗脱球囊治疗冠状动脉支架内再狭窄的比较：倾向性评分匹配比较的 1 年随访（BIORESOLVE-ISR 研究）。
Catheter Cardiovasc Interv. 2018 Oct 1;92(4):668-677. doi: 10.1002/ccd.27473. Epub 2018 Jan 22.
3
Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.生物可吸收血管支架治疗支架内再狭窄患者：RIBS VI 研究。
JACC Cardiovasc Interv. 2017 Sep 25;10(18):1841-1851. doi: 10.1016/j.jcin.2017.06.064. Epub 2017 Aug 30.
4
Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).生物可吸收血管支架与依维莫司洗脱金属支架治疗 ST 段抬高型心肌梗死：倾向评分匹配比较的 1 年结果：BVS-EXAMINATION 研究（生物可吸收血管支架——依维莫司洗脱冠状动脉支架治疗 ST 段抬高型心肌梗死患者的临床评估）。
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197. doi: 10.1016/j.jcin.2014.10.005.
5
Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.依维莫司洗脱生物可吸收血管支架与耐用聚合物依维莫司洗脱金属支架在1年随访时的安全性和有效性评估：一项研究的系统评价和荟萃分析
Int J Cardiol. 2016 Oct 15;221:1087-94. doi: 10.1016/j.ijcard.2016.07.101. Epub 2016 Jul 9.
6
Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.生物可吸收血管支架治疗冠状动脉支架内再狭窄的长期临床结果：意大利多中心经验。
Circ Cardiovasc Interv. 2016 Apr;9(4):e003148. doi: 10.1161/CIRCINTERVENTIONS.115.003148.
7
A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.紫杉醇洗脱球囊与依维莫司洗脱支架治疗任何部位支架内再狭窄的随机比较：DARE 试验。
JACC Cardiovasc Interv. 2018 Feb 12;11(3):275-283. doi: 10.1016/j.jcin.2017.10.024. Epub 2017 Nov 7.
8
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.依维莫司洗脱冠状动脉支架与依维莫司洗脱生物可吸收血管支架的比较。
J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. doi: 10.1016/j.jacc.2014.12.017.
9
Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.依维莫司洗脱支架用于裸金属和药物洗脱支架内再狭窄患者：RIBS IV和V试验患者水平汇总分析结果
Circ Cardiovasc Interv. 2016 Jul;9(7). doi: 10.1161/CIRCINTERVENTIONS.115.003479.
10
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.依维莫司洗脱冠状动脉支架和生物雷帕霉素洗脱冠状动脉支架与依维莫司洗脱生物可吸收血管支架的比较：EVERBIO II试验的两年临床结果。
Int J Cardiol. 2017 Sep 15;243:121-125. doi: 10.1016/j.ijcard.2017.05.053. Epub 2017 May 12.

引用本文的文献

1
The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.XINSORB 生物可吸收支架植入后标准与延长双联抗血小板治疗（SPARTA）试验：一项随机对照试验的研究方案。
Trials. 2023 Jan 20;24(1):49. doi: 10.1186/s13063-022-07028-8.
2
Evaluation of Therapeutic Effects of Computed Tomography Imaging Classification Algorithm-Based Transcatheter Arterial Chemoembolization on Primary Hepatocellular Carcinoma.基于计算机断层成像分类算法的经导管动脉化疗栓塞治疗原发性肝癌的疗效评价。
Comput Intell Neurosci. 2022 Apr 22;2022:5639820. doi: 10.1155/2022/5639820. eCollection 2022.
3
Three-year clinical outcomes of a sirolimus-eluting bioresorbable scaffold (XINSORB) and a metallic stent to treat coronary artery stenosis.
西罗莫司洗脱生物可吸收支架（XINSORB）与金属支架治疗冠状动脉狭窄的三年临床结果
Ann Transl Med. 2020 Nov;8(22):1489. doi: 10.21037/atm-20-6739.
4
In vivo and in vitro evaluation of a biodegradable magnesium vascular stent designed by shape optimization strategy.采用形状优化策略设计的可生物降解镁血管支架的体内和体外评价。
Biomaterials. 2019 Nov;221:119414. doi: 10.1016/j.biomaterials.2019.119414. Epub 2019 Aug 5.